Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model

Treatment with neutralizing monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) contributes to COVID-19 management. Unfortunately, SARS-CoV-2 variants escape several of these recently approved mAbs, highlighting the need for additional discovery and deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Imbrechts, Maya, Maes, Wim, Ampofo, Louanne, Van den Berghe, Nathalie, Calcoen, Bas, Van Looveren, Dominique, Kerstens, Winnie, Rasulova, Madina, Vercruysse, Thomas, Noppen, Sam, Abdelnabi, Rana, Foo, Caroline, Hollevoet, Kevin, Maes, Piet, Zhang, Xin, Jochmans, Dirk, Ven, Karen, Lammertyn, Jeroen, Vanhoorelbeke, Karen, Callewaert, Nico, De Munter, Paul, Schols, Dominique, Thibaut, Hendrik Jan, Neyts, Johan, Declerck, Paul, Geukens, Nick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250818/
https://www.ncbi.nlm.nih.gov/pubmed/35813873
http://dx.doi.org/10.1016/j.isci.2022.104705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250818/
https://www.ncbi.nlm.nih.gov/pubmed/35813873
http://dx.doi.org/10.1016/j.isci.2022.104705

Ejemplares similares